BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: A Canadian perspective. Can Urol Assoc J 2015;9:242-7. [PMID: 26316906 DOI: 10.5489/cuaj.2711] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Szymański JK, Słabuszewska-Jóźwiak A, Jakiel G. Fowler's Syndrome-The Cause of Urinary Retention in Young Women, Often Forgotten, but Significant and Challenging to Treat. Int J Environ Res Public Health 2021;18:3310. [PMID: 33806865 DOI: 10.3390/ijerph18063310] [Reference Citation Analysis]
2 Murray B, Hessami SH, Gultyaev D, Lister J, Dmochowski R, Gillard KK, Stanisic S, Tung A, Boer R, Kaplan S. Cost–effectiveness of overactive bladder treatments: from the US payer perspective. Journal of Comparative Effectiveness Research 2019;8:61-71. [DOI: 10.2217/cer-2018-0079] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
3 Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Zylstra S, Kan F, Berg KC. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol 2018;199:229-36. [PMID: 28709886 DOI: 10.1016/j.juro.2017.07.010] [Cited by in Crossref: 76] [Cited by in F6Publishing: 51] [Article Influence: 19.0] [Reference Citation Analysis]
4 Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Jairam R, Perrouin-Verbe M, Elneil S. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder. Neurourol Urodyn 2018;37:S9-S16. [PMID: 29315785 DOI: 10.1002/nau.23465] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
5 Abello A, Das AK. Electrical neuromodulation in the management of lower urinary tract dysfunction: evidence, experience and future prospects. Ther Adv Urol 2018;10:165-73. [PMID: 29623108 DOI: 10.1177/1756287218756082] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
6 Marcelissen T, Cornu JN, Antunes-Lopes T, Geavlete B, Delongchamps NB, Rashid T, Rieken M, Rahnama'i MS. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment? Eur Urol Focus 2018;4:760-7. [PMID: 29807823 DOI: 10.1016/j.euf.2018.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 4.3] [Reference Citation Analysis]
7 Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, Comiter C, Culkin D, Bennett J, Zylstra S, Kan F, Thiery E. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation. Urology 2016;94:57-63. [PMID: 27131966 DOI: 10.1016/j.urology.2016.04.024] [Cited by in Crossref: 76] [Cited by in F6Publishing: 56] [Article Influence: 15.2] [Reference Citation Analysis]
8 Tay LJ, Harry D, Malde S, Sahai A. Cost Effectiveness of Sacral Neuromodulation and OnabotulinumtoxinA in Managing Refractory Idiopathic Overactive Bladder. Urology 2021;149:1-10. [PMID: 33227305 DOI: 10.1016/j.urology.2020.11.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Gahzi AA, Banakhar MA, Elterman DS, Hassouna M. Radiographic Position of the Electrode as a Predictor of the Outcome of InterStim Therapy. Int Neurourol J 2017;21:289-94. [PMID: 29298468 DOI: 10.5213/inj.1734942.471] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Apostolidis A, Averbeck MA, Sahai A, Rahnama'i MS, Anding R, Robinson D, Gravas S, Dmochowski R. Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015). Neurourol Urodynam 2017;36:882-93. [DOI: 10.1002/nau.23170] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
11 Wallace KM, Drake MJ. Overactive bladder. F1000Res 2015;4:F1000 Faculty Rev-1406. [PMID: 26918151 DOI: 10.12688/f1000research.7131.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Gerjevic KA, Ahmad S, Strohbehn K, Riblet N. Cost-Effectiveness Analysis Between Sacral Neuromodulation and OnabotulinumtoxinA for the Treatment of Refractory Overactive Bladder in Women: A Systematic Review. Female Pelvic Med Reconstr Surg 2021;27:481-7. [PMID: 34074937 DOI: 10.1097/SPV.0000000000001074] [Reference Citation Analysis]
13 Noblett KL, Dmochowski RR, Vasavada SP, Garner AM, Liu S, Pietzsch JB. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome: Cost Profile and Budget Impact of Rechargeable SNM Devices for OAB. Neurourol Urodynam 2017;36:727-33. [DOI: 10.1002/nau.23008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
14 de Oliveira PS, Reis JP, de Oliveira TR, Martinho D, E Silva RP, Marcelino J, Gaspar S, Martins F, Lopes T. The Impact of Sacral Neuromodulation on Sexual Dysfunction. Curr Urol 2019;12:188-94. [PMID: 31602184 DOI: 10.1159/000499307] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]